http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2050664-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-2479 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-2433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-2491 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-4407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-2408 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-2458 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-4465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-252 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-252 |
| filingDate | 1991-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_596b9a1463840ce87f4371aaa269a8e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f1cdb42cc7309ac84576c1cc8d932e9 |
| publicationDate | 1993-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2050664-A1 |
| titleOfInvention | Antitumor aldophosphamide analogs |
| abstract | ABSTRACT OF THE DISCLOSURE NOVEL ANTITOMOR ALDOPHOSPHAMIDE ANALOGS A compound having the structure: wherein R is CH3, C2H5, C3H7, t-C4H9 or C6H5; R1 is NH2, NHCH3, NHC2H5, NHC3H7, NHC4H9, NHCH2CH2Cl, NHC6H5, N(CH3)2, N(C2H5)2, N(C3H7)2, NCH3(C2H5), NCH3(C3H7), N(CH2CH2Cl)2, NHOH, NHNHCO2CH2C6H5, NHNHCO2C(CH3)3, OCH3, OC2H5, OC3H7, OC4H9, OC6H5, OC2C6H5, CH3, C2H5, C3H7, C4H9, CH2NO2 OR CH2NH2; and R2 is NHCH2Cl or N(CH2CH2Cl)2. These compounds may be used to eliminate occult leukemic clonogenic cells from bone marrow by contacting the bone marrow with a solution comprising levels of said compound sufficient to eliminate occult leukemic clonogenic cells. Analogously, tumor cells in a host or organ of a host may be eliminated by treatment of the host or host's organ with a compound of this description. Compounds of this description are stable aldophosphamide analogs activatable by the action of an esterase and a subsequent E-2 elimination reaction to form acrolein and a phosphoramidic mustard of the formula: A stable aldophosphamide analog activatable by the action of an esterase and a subsequent spontaneous E-2 elimination reaction to form acrolein and a phosphoramidic mustard, said phosphoramidic mustard having the formula R is NH2, NHCH3, NHC2H5, NHC3H7, NHC4H9, NHCH2CH2Cl, NHC6H5, N(CH3)2, N(C2H5)2, N(C3H7)2, NCH3(C2H5), NCH3(C3H7), N(CH2CH2Cl)2, NHOH, NHNHCO2CH2C6H5, NHNHCO2C(CH3)3, OCH3, OC2H5, OC3H7, OC4H9, OC6H5, OC2C6H5, CH3, C2H5, C3H7, C4H9, CH2NO2 or CH2NH2; and R1 is NHCH2CH2Cl or N(CH2CH2Cl)2. |
| priorityDate | 1989-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 424.